Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship.

By Rebecca R. Roberts, Bala Hota, I. Ahmad, R. Douglas Scott II, S. Foster, Fauzia Abbasi, S. Schabowski, L. Kampe, Ginevra G. Ciavarella, M. Supino and 4 more. Clinical Infectious Diseases, 2009

709 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Critical Care and Intensive Care Medicine, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/5c08b0c79efc81dc017791a04e388d9c3707bed2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Microbiology and Biotechnology

1. Kim Lewis
2. K. Bush
3. A. Srinivasan
4. S. Levy
5. David L. Paterson
6. G. Jacoby
7. P. Bradford
8. S. Cosgrove

In Critical Care and Intensive Care Medicine

1. Yehuda Carmeli
2. David L. Paterson

In Molecular Medicine

1. K. Bush
2. L. Piddock
3. Kim Lewis
4. David L. Paterson
5. C. Giske
6. Carolina S. Silva
7. T. Walsh
8. M. O. Santos

Citations in the corpus

• Strategies and molecular tools to fight antimicrobial resistance: resistome, transcriptome, and antimicrobial peptides (2013, background): “…that about two million Americans per year develop hospital infections, mostly caused by multidrug-resistant bacteria pathogens, which increases treatment costs in about U$ 21 million to U$ 34 billion, compared to antibiotic-susceptible pathogens (Roberts et al., 2009; Spellberg et al., 2011).”
• Tackling antibiotic resistance (2011, background): “In the United States, antibiotic-resistant infections are responsible for $20 billion per year in excess health care costs, $35 billion per year in societal costs and 8 million additional hospital days per yea”
• Bacteria Antibiotic Resistance: New Challenges and Opportunities for Implant-Associated Orthopaedic Infections (2017, background): “alone, antibioticresistant bacteria cause at least 2 million infections, 23,000 deaths a year,(6) and $55-70 billion per year in economic impact.(12,13) In Europe, approximately 25,000 people die annually due to MDR bacterial infections, along with a s1.”
• Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. (2012, background): “Infections with MDROs can lead to inadequate or delayed antimicrobial therapy, and are associated with poorer patient outcomes [1–4].”